Strategic advisory that holds up under scrutiny.
We advise founders, research institutions, and global health leaders on commercialization decisions that need to withstand investor and board review.
Three core advisory engagements.
01.
Commercialization strategy for research spin-offs.
We work with research institutions, technology transfer offices, and spin-off teams to define the commercial pathway from research output to investable company. This includes application field selection, value proposition validation, and the structuring of the founding team and IP arrangement.
02.
Validation and prioritization frameworks.
Many ventures and corporate innovation teams hold more opportunities than they can pursue. We bring structured frameworks, including our Application Field Matrix and Commercial Validation Matrix, to prioritize where to focus and which paths to deprioritize, on evidence rather than intuition.
03.
Investor readiness reviews.
Ahead of fundraising rounds, we run structured investor readiness reviews across the seven dimensions of our Venture Readiness Framework, identifying the gaps that institutional investors will probe and the remediation steps to close them before approaching the round.
Founders.
Early-stage health and life sciences teams making structural decisions about commercialization path, validation strategy, and round structuring.
Research institutions.
Universities, research clinics, and technology transfer offices structuring spin-offs and commercialization programs.
Global health leaders.
Pharma, MedTech, and diagnostics organizations running corporate venturing programs or new business unit assessments.
Frameworks We Deploy
Frameworks we deploy in Advise.
Every advisory engagement runs on the same framework family. Three frameworks anchor the work in Advise.
01
AFM
Used to select the right application field before scaling investment in any single direction.
02
VRL
Used to map current readiness across all six dimensions and define the next concrete stage gate.
03
CVC
Used to validate willingness to pay before commercial commitments are made.
Every advisory engagement is structured AI-First. We use AI augmentation throughout discovery, framework application, and synthesis, so our clients benefit from depth that would be hard to deliver on a human-only basis. Where AI does not add measurable value, we do not force it. Read our full AI-First approach →